The goal of this proposal is to continue our investigations of the limbic- hypothalamo-pituitary adrenal (LHPA) axis in normal humans and its dysregulation in major depression. there is general agreement that this axis is altered in many subjects suffering from affective disorders, although the nature of the disruption and the sources of variance remain ill understood. During the past 5 years of funding, we have used a combination of peptide measures and challenge paradigms to study the status of the LHPA in depressed subjects and have found that a) following a dexamethasone challenge, a larger proportion of these patients appears disrupted at the level of the pituitary than can be discerned with cortisol measures. b) as a group, these patients are less responsive to secretagogue challenge, regardless of their circulating steroid levels. c) depressed subjects appear to have increased suprapituitary drive, at least in the evening hours, i.e. at the nadir of the circadian rhythm. d) they appear to be insensitive to rapidly rising steroid levels, a feedback mechanism thought to be mediated in the brain, most likely in hippocampus. e) the expression of these disruptions is greatly influenced by two individual variables: age, sex, and their interactions. In this proposal, we attempt to more clearly """"""""isolate"""""""" the elements of the axis by using novel challenge paradigms that focus primarily on pituitary versus brain, in order to investigate their relative contributions to the axis. In order to do so, a number of studies are proposed to calibrate and validate these paradigms in normal controls prior to their use in psychiatric patients. The results will shed light on the normal mechanisms governing LHPA in humans, as well as their alteration in affective disorders.
One aim i s focused on more fully """"""""isolating"""""""" the pituitary by administering simultaneously both secretagogues, corticotropin releasing hormone (CRH) and vasopressin (AVP) while blocking cortisol synthesis. This is followed by studies on the nature of steroid feedback at the level of the pituitary. The remaining paradigms attempt to """"""""move into the brain"""""""" by focusing on mechanisms such as fast feedback which are known to be mediated at a suprapituitary level. We shall investigate the nature of the increased drive, the role of specific glucorticoid and mineralcorticoid receptors (GR and MR) in controlling it, the disruption of fast feedback following a stress challenge, and the contribution of the two receptors in that mechanism. Finally, studies will be carried out in aged and euthymic patients with a history of repeated depressive or manic depressive episodes to determine whether their stress responses become altered even when out of episode. These studies have been shaped by our improved understanding of the LHPA in rat (Project I), and the interpretation of the results will be aided by the funding of the postmortem studies in Project III.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Program Projects (P01)
Project #
5P01MH042251-10
Application #
5214638
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
10
Fiscal Year
1996
Total Cost
Indirect Cost
Crane, Natania A; Jenkins, Lisanne M; Bhaumik, Runa et al. (2017) Multidimensional prediction of treatment response to antidepressants with cognitive control and functional MRI. Brain 140:472-486
Hillhouse, Todd M; Porter, Joseph H (2015) A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol 23:1-21
Meyers, K K; Crane, N A; O'Day, R et al. (2015) Smoking history, and not depression, is related to deficits in detection of happy and sad faces. Addict Behav 41:210-7
Lohoff, F W; Hodge, R; Narasimhan, S et al. (2014) Functional genetic variants in the vesicular monoamine transporter 1 modulate emotion processing. Mol Psychiatry 19:129-39
Votruba, Kristen L; Langenecker, Scott A (2013) Factor structure, construct validity, and age- and education-based normative data for the Parametric Go/No-Go Test. J Clin Exp Neuropsychol 35:132-46
Tomita, Hiroaki; Ziegler, Mary E; Kim, Helen B et al. (2013) G protein-linked signaling pathways in bipolar and major depressive disorders. Front Genet 4:297
Turner, Cortney A; Watson, Stanley J; Akil, Huda (2012) The fibroblast growth factor family: neuromodulation of affective behavior. Neuron 76:160-74
Vederman, Aaron C; Weisenbach, Sara L; Rapport, Lisa J et al. (2012) Modality-specific alterations in the perception of emotional stimuli in Bipolar Disorder compared to Healthy Controls and Major Depressive Disorder. Cortex 48:1027-34
Turner, Cortney A; Clinton, Sarah M; Thompson, Robert C et al. (2011) Fibroblast growth factor-2 (FGF2) augmentation early in life alters hippocampal development and rescues the anxiety phenotype in vulnerable animals. Proc Natl Acad Sci U S A 108:8021-5
Mickey, Brian J; Zhou, Zhifeng; Heitzeg, Mary M et al. (2011) Emotion processing, major depression, and functional genetic variation of neuropeptide Y. Arch Gen Psychiatry 68:158-66

Showing the most recent 10 out of 75 publications